{"downloaded": true, "htmlmade": false, "full": {"id": "29720244", "source": "MED", "pmid": "29720244", "pmcid": "PMC5932813", "fullTextIdList": {"fullTextId": "PMC5932813"}, "doi": "10.1186/s13063-018-2647-y", "title": "Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).", "authorString": "Gudiol C, Nicolae S, Royo-Cebrecos C, Aguilar-Guisado M, Montero I, Mart\u00edn-Gandul C, Perayre M, Berbel D, Encuentra M, Arnan M, Cisneros-Herreros JM, Carratal\u00e0 J.", "authorList": {"author": [{"fullName": "Gudiol C", "firstName": "C", "lastName": "Gudiol", "initials": "C", "authorId": {"@type": "ORCID", "#text": "0000-0003-3095-4422"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. carlotagudiol@gmail.com."}, {"affiliation": "University of Barcelona, Barcelona, Spain. carlotagudiol@gmail.com."}, {"affiliation": "REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain. carlotagudiol@gmail.com."}]}}, {"fullName": "Nicolae S", "firstName": "S", "lastName": "Nicolae", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain."}}}, {"fullName": "Royo-Cebrecos C", "firstName": "C", "lastName": "Royo-Cebrecos", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain."}, {"affiliation": "REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain."}]}}, {"fullName": "Aguilar-Guisado M", "firstName": "M", "lastName": "Aguilar-Guisado", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Roc\u00edo-Institute of Biomedicine of Seville, Seville, Spain."}, {"affiliation": "REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain."}]}}, {"fullName": "Montero I", "firstName": "I", "lastName": "Montero", "initials": "I", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, University Hospital Virgen del Roc\u00edo-Institute of Biomedicine of Seville, Seville, Spain."}}}, {"fullName": "Mart\u00edn-Gandul C", "firstName": "C", "lastName": "Mart\u00edn-Gandul", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Roc\u00edo-Institute of Biomedicine of Seville, Seville, Spain."}, {"affiliation": "REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain."}]}}, {"fullName": "Perayre M", "firstName": "M", "lastName": "Perayre", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pharmacy Department, Clinical Trial Unit, Institut Catal\u00e0 d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain."}}}, {"fullName": "Berbel D", "firstName": "D", "lastName": "Berbel", "initials": "D", "authorId": {"@type": "ORCID", "#text": "0000-0002-3689-3360"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Microbiology Department, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain."}}}, {"fullName": "Encuentra M", "firstName": "M", "lastName": "Encuentra", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Biostatistics. Clinical Research Unit, Institut Catal\u00e0 d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain."}}}, {"fullName": "Arnan M", "firstName": "M", "lastName": "Arnan", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Haematology Department, Institut Catal\u00e0 d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain."}}}, {"fullName": "Cisneros-Herreros JM", "firstName": "J M", "lastName": "Cisneros-Herreros", "initials": "JM", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Roc\u00edo-Institute of Biomedicine of Seville, Seville, Spain."}, {"affiliation": "REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain."}]}}, {"fullName": "Carratal\u00e0 J", "firstName": "J", "lastName": "Carratal\u00e0", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0003-3209-2563"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain."}, {"affiliation": "University of Barcelona, Barcelona, Spain."}, {"affiliation": "REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-5001-672X"}, {"@type": "ORCID", "#text": "0000-0002-3689-3360"}, {"@type": "ORCID", "#text": "0000-0003-3095-4422"}, {"@type": "ORCID", "#text": "0000-0003-3209-2563"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "1", "volume": "19", "journalIssueId": "2678375", "dateOfPublication": "2018 May", "monthOfPublication": "5", "yearOfPublication": "2018", "printPublicationDate": "2018-05-01", "journal": {"title": "Trials", "ISOAbbreviation": "Trials", "medlineAbbreviation": "Trials", "NLMid": "101263253", "ISSN": "1745-6215", "ESSN": "1745-6215"}}, "pubYear": "2018", "pageInfo": "264", "abstractText": "BACKGROUND:Catheter-related bloodstream infection (CRBSI) is one of the most frequent complications in patients with cancer who have central venous catheters (CVCs) implanted and is associated with substantial morbidity and mortality. Taurolidine is a non-antibiotic agent with broad-spectrum antimicrobial activity, which has been used as a lock solution to prevent CRBSI in some settings. However, little is known about its usefulness in high-risk adult neutropenic patients with cancer. This prospective randomised clinical trial aims to test the hypothesis that taurolidine-citrate lock solution is more effective than placebo for preventing catheter infection in neutropenic haematological patients. METHODS:This study is a prospective, multicentre, randomised, double-blinded, parallel, superiority, placebo-controlled trial. Patients with haematological cancer who are expected to develop prolonged neutropenia (>\u20097\u00a0days) and who have a non-tunnelled CVC implanted will be randomised to receive prophylactic taurolidine-citrate-heparin solution using a lock technique (study group) or heparin alone (placebo group). The primary endpoint will be bacterial colonisation of the CVC hubs. The secondary endpoints will be the incidence of CRBSI, CVC removal, adverse events, and 30-day case-fatality rate. DISCUSSION:The lock technique is a preventive strategy that inhibits bacterial colonisation in the catheter hubs, which is the initial step of endoluminal catheter colonisation and the development of infection. Taurolidine is a nontoxic agent that does not develop antibiotic resistance because it acts as an antiseptic rather than an antibiotic. Taurolidine has shown controversial results in the few trials conducted in cancer patients. These studies have important limitations due to the lack of data on adult and/or high-risk neutropenic patients, the type of catheters studied (tunnelled or ports), and the lack of information regarding the intervention (e.g. dwelling of the solution, time, and periodicity of the lock technique). If our hypothesis is proven, the study could provide important solid evidence on the potential usefulness of this preventive procedure in a population at high risk of CRBSI, in whom this complication may significantly impair patient outcome. TRIAL REGISTRATION:ISRCTN, ISRCTN47102251 . Registered on 9 September 2015.", "affiliation": "Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. carlotagudiol@gmail.com.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Clinical Trial Protocol", "research-article", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "PI13/01474", "agency": "Instituto de Salud Carlos III, Spanish Ministry of Economy", "orderIn": "0"}, {"grantId": "REIPI RD12/0015", "agency": "Insituto de Salud Carlos III, Spanish Ministry of Economy", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Hematologic Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neutropenia", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "Y"}, {"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Citrates", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Taurine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "AA", "qualifierName": "analogs & derivatives", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Thiadiazines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Anti-Infective Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Catheterization, Central Venous", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "Y"}, {"abbreviation": "IS", "qualifierName": "instrumentation", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Device Removal"}, {"majorTopic_YN": "N", "descriptorName": "Risk Factors"}, {"majorTopic_YN": "N", "descriptorName": "Prospective Studies"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Catheters, Indwelling", "meshQualifierList": {"meshQualifier": {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Time Factors"}, {"majorTopic_YN": "N", "descriptorName": "Spain"}, {"majorTopic_YN": "N", "descriptorName": "Multicenter Studies as Topic"}, {"majorTopic_YN": "N", "descriptorName": "Catheter-Related Infections", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "N"}, {"abbreviation": "MI", "qualifierName": "microbiology", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Central Venous Catheters", "meshQualifierList": {"meshQualifier": {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Equivalence Trials as Topic"}]}, "keywordList": {"keyword": ["Neutropenia", "Antibiotic Lock Technique", "Haematological Patients", "Catheter-related Bloodstream Infection", "Lock Solution", "Central Venous Catheter Infection", "Taurolidine-citrate"]}, "chemicalList": {"chemical": [{"name": "Antineoplastic Agents", "registryNumber": "0"}, {"name": "Citrates", "registryNumber": "0"}, {"name": "Anti-Infective Agents", "registryNumber": "0"}, {"name": "Thiadiazines", "registryNumber": "0"}, {"name": "taurolidine", "registryNumber": "8OBZ1M4V3V"}, {"name": "Taurine", "registryNumber": "1EQV5MLY3D"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1186/s13063-018-2647-y"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5932813"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5932813?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "1", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-03-14", "dateOfCreation": "2018-05-04", "firstIndexDate": "2018-05-04", "fullTextReceivedDate": "2020-07-12", "dateOfRevision": "2019-03-14", "electronicPublicationDate": "2018-05-02", "firstPublicationDate": "2018-05-02"}, "htmllinks": "https://europepmc.org/articles/PMC5932813", "abstract": "BACKGROUND:Catheter-related bloodstream infection (CRBSI) is one of the most frequent complications in patients with cancer who have central venous catheters (CVCs) implanted and is associated with substantial morbidity and mortality. Taurolidine is a non-antibiotic agent with broad-spectrum antimicrobial activity, which has been used as a lock solution to prevent CRBSI in some settings. However, little is known about its usefulness in high-risk adult neutropenic patients with cancer. This prospective randomised clinical trial aims to test the hypothesis that taurolidine-citrate lock solution is more effective than placebo for preventing catheter infection in neutropenic haematological patients. METHODS:This study is a prospective, multicentre, randomised, double-blinded, parallel, superiority, placebo-controlled trial. Patients with haematological cancer who are expected to develop prolonged neutropenia (>\u20097\u00a0days) and who have a non-tunnelled CVC implanted will be randomised to receive prophylactic taurolidine-citrate-heparin solution using a lock technique (study group) or heparin alone (placebo group). The primary endpoint will be bacterial colonisation of the CVC hubs. The secondary endpoints will be the incidence of CRBSI, CVC removal, adverse events, and 30-day case-fatality rate. DISCUSSION:The lock technique is a preventive strategy that inhibits bacterial colonisation in the catheter hubs, which is the initial step of endoluminal catheter colonisation and the development of infection. Taurolidine is a nontoxic agent that does not develop antibiotic resistance because it acts as an antiseptic rather than an antibiotic. Taurolidine has shown controversial results in the few trials conducted in cancer patients. These studies have important limitations due to the lack of data on adult and/or high-risk neutropenic patients, the type of catheters studied (tunnelled or ports), and the lack of information regarding the intervention (e.g. dwelling of the solution, time, and periodicity of the lock technique). If our hypothesis is proven, the study could provide important solid evidence on the potential usefulness of this preventive procedure in a population at high risk of CRBSI, in whom this complication may significantly impair patient outcome. TRIAL REGISTRATION:ISRCTN, ISRCTN47102251 . Registered on 9 September 2015.", "Keywords": ["Neutropenia", "Antibiotic Lock Technique", "Haematological Patients", "Catheter-related Bloodstream Infection", "Lock Solution", "Central Venous Catheter Infection", "Taurolidine-citrate"], "pdflinks": "https://europepmc.org/articles/PMC5932813?pdf=render", "journaltitle": "Trials", "authorinfo": ["Gudiol C", "Nicolae S", "Royo-Cebrecos C", "Aguilar-Guisado M", "Montero I", "Mart\u00edn-Gandul C", "Perayre M", "Berbel D", "Encuentra M", "Arnan M", "Cisneros-Herreros JM", "Carratal\u00e0 J"], "title": "Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT)."}